Cellectar BioSciences, Inc. (CLRB)
Stock Price:
$1.40 USD
0.00 (0.00%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
33.60M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-14.43M |
| Shares Out |
24.00M |
| EPS (ttm) |
-1.63 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$1.40 |
| Previous Close |
$1.40 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
1.40 |
| Day's Range |
1.38 - 1.42 |
| Day's Volume |
423,366 |
| 52-Week Range |
1.01 - 3.33 |
More Stats
| Market Cap |
33.60M |
| Enterprise Value |
27.01M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.00M |
| Float |
7.88M |
| EPS (basic) |
-1.63 |
| EPS (diluted) |
-1.63 |
| FCF / Share |
-1.32 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
92,954 |
| Short Ratio |
0.38 |
| Short % of Float |
1.22% |
| Beta |
1.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
8.32 |
| Revenue |
n/a |
| Operating Income |
-14.51M |
| Net Income |
-14.43M |
| Free Cash Flow |
-12.42M |
| Net Cash |
6.59M |
| Net Cash / Share |
0.27 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-84.91% |
| ROE |
-191.20% |
| ROIC |
4,015.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.48*
(291.43% upside)
Low
3.00
Current: $1.40
High
10.00
Target: 5.48
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -14.18 | -13.33 | -13.60 | -9.45 | -8.76 | -9.89 | -12.40 | -8.75 | -7.04 | -4.19 |
| Net Income | -14.09 | -13.24 | -13.56 | -6.18 | -5.50 | -8.05 | -10.78 | -8.80 | -7.44 | -4.56 |
| Shares Outstanding | 7.68 | 2.96 | 1.40 | 0.44 | 0.08 | 0.05 | 0.03 | 0.02 | 0.01 | 0.01 |
| Earnings Per Share | -1.84 | -5.23 | -10.70 | -21.40 | -70.30 | -175.30 | -386.00 | -460.00 | -620.00 | -720.00 |
| Operating Cash Flow | -11.69 | -11.44 | -11.02 | -8.28 | -8.21 | -8.84 | -9.15 | -6.59 | -5.97 | -3.38 |
| Capital Expenditures | -0.02 | -0.33 | -0.35 | -0.07 | -0.06 | -0.03 | -0.15 | -0.10 | -0.12 | - |
| Free Cash Flow | -11.72 | -11.77 | -11.37 | -8.35 | -8.27 | -8.87 | -9.30 | -6.68 | -6.09 | -3.38 |
| Cash & Equivalents | 10.61 | 13.31 | 10.06 | 11.50 | 3.91 | 9.48 | 2.47 | 6.73 | 5.56 | 1.23 |
| Total Debt | 0.53 | - | 0.01 | 0.09 | 0.34 | 0.46 | 0.45 | 0.45 | 0.46 | 3.86 |
| Net Cash / Debt | 10.09 | 13.31 | 10.06 | 11.41 | 3.57 | 9.01 | 2.02 | 6.28 | 5.10 | -2.63 |
| Assets | 12.25 | 15.05 | 12.87 | 15.32 | 7.60 | 13.42 | 6.82 | 11.48 | 10.56 | 4.80 |
| Liabilities | 3.19 | 1.79 | 2.12 | 1.78 | 5.95 | 6.72 | 5.12 | 1.32 | 1.08 | 4.67 |
| Book Value | 9.06 | 13.26 | 10.75 | 13.54 | 1.65 | 6.70 | 1.70 | 10.16 | 9.48 | 0.13 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cellectar BioSciences, Inc. |
| Country |
United States |
| Employees |
8 |
| CEO |
James V. Caruso |
Stock Information
| Ticker Symbol |
CLRB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CLRB |
Description
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.